Carbazeran is a selective inhibitor of phosphodiesterase 3 (PDE3), primarily used in research settings to study its effects on the cardiovascular system. By increasing intracellular cyclic AMP (cAMP) levels, it acts as a vasodilator and positive inotrope, making it valuable for investigating mechanisms related to blood pressure regulation, vascular function, and cardiac contractility. Additionally, it has been explored for its potential therapeutic applications in treating conditions like hypertension, heart failure, and angina, though it is not widely used clinically. Its role in experimental pharmacology helps scientists understand the pathways involved in cardiovascular diseases and develop new treatment strategies.